McKesson (MCK)
(Delayed Data from NYSE)
$607.51 USD
+58.20 (10.60%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$607.51 USD
+58.20 (10.60%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.
Invest Like Warren Buffett With These 3 Stocks
by Derek Lewis
The Oracle of Omaha has been on the offensive in 2022, recognizing value in a challenging market.
Neogen (NEOG) Finalizes Food Safety Business Merger With 3M
by Zacks Equity Research
The combination of Neogen (NEOG) and 3M's Food Safety division will capitalize on the ongoing growth trends in sustainability, food safety and supply chain integrity.
SmileDirectClub (SDC) Faces Low Aligner Shipment, Margin Woe
by Zacks Equity Research
The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
CVS Health (CVS) to Buy Signify Health, Grow in Home Healthcare
by Zacks Equity Research
According to CVS Health (CVS), Signify Health, as a leading healthcare platform, will play a critical role in advancing the company's healthcare services strategy.
Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care
by Zacks Equity Research
Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.
Here's Why You Should Hold on to BD (BDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
S&P 500 Likely to Trade Rangebound in September: 5 Picks
by Nalak Das
We have narrowed our search to five S&P 500 stocks that have popped year to date despite the index's bloodbath. These are: ADM, CTVA, MCK, MPC and XOM.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) segmental results and robust bookings and backlog growth.
Zimmer Biomet (ZBH) Signs Co-Marketing Agreement for HipInsight
by Zacks Equity Research
Zimmer Biomet's (ZBH) HipInsight is a mixed reality-based visualization tool that will aid surgeons in precise implant placement and alignment during total hip replacement.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
Masimo's (MASI) Latest Watch to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) full-market consumer release of the Masimo W1 and other related launches is likely to significantly improve RPM.
Chemed's (CHE) Roto-Rooter Growth Aids, Macro Challenges Ail
by Zacks Equity Research
Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.
Here's Why You Should Retain Haemonetics (HAE) Stock Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.
Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail
by Zacks Equity Research
Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.
McKesson (MCK) Up 7.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nevro's (NVRO) PDN Therapy Gets Positive Coverage Updates
by Zacks Equity Research
Latest favorable coverage decisions for Nevro's (NVRO) PDN Therapy are expected to serve a wider patient pool.
3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Here's Why You Should Hold on to Chemed (CHE) Stock Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.
Medtronic (MDT) Obtains U.S. Distribution Rights for BioButton
by Zacks Equity Research
Medtronic's (MDT) new deal with BioIntelliSense will ensure accessibility to BioButton for continuous vital sign measurements of general care patients in the United States.
Boston Scientific (BSX) Grows Operationally Amid Macro Issues
by Zacks Equity Research
In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.
Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter 2023 results were adversely impacted by unfavorable currency movements.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.
Veeva Systems (VEEV) Beats on Q2 Earnings, Revises FY23 View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both of its segments.